Variation in treatment preferences of pulmonary exacerbations among Australian and New Zealand cystic fibrosis physicians
CONCLUSIONS: Variation exists among CF physicians in their preferred choice of primary antibiotic and use of dornase alfa. These preferences are driven by professional opinion, possibly reflecting a lack of evidence to base policy recommendations. Evidence from high-quality clinical trials is needed to inform physician decision making.PMID:34266854 | DOI:10.1136/bmjresp-2021-000956 (Source: Respiratory Care)
Source: Respiratory Care - July 16, 2021 Category: Respiratory Medicine Authors: Grace Currie Anna Tai Tom Snelling Andr é Schultz Source Type: research
Proteome profiling of recombinant DNase therapy in reducing NETs and aiding recovery in COVID-19 patients
Mol Cell Proteomics. 2021 Jun 14:100113. doi: 10.1016/j.mcpro.2021.100113. Online ahead of print.ABSTRACTSevere COVID-19 can result in pneumonia and acute respiratory failure. Accumulation of mucus in the airways is a hall mark of the disease and can result in hypoxemia. Here, we show that quantitative proteome analysis of the sputum from severe COVID-19 patients reveal high levels of neutrophil extracellular trap(s) (NETs) components, which was confirmed by microscopy. Extracellular DNA from excessive NET formation can increase sputum viscosity and can lead to acute respiratory distress syndrome (ARDS). Recombinant human ...
Source: Molecular and Cellular Proteomics : MCP - June 17, 2021 Category: Molecular Biology Authors: Jane Fisher Tirthankar Mohanty Christofer Karlsson S M Hossein Khademi Erik Malmstr öm Attila Frigyesi Pontus Nordenfelt Johan Malmstrom Adam Linder Source Type: research
Proteome profiling of recombinant DNase therapy in reducing NETs and aiding recovery in COVID-19 patients
Mol Cell Proteomics. 2021 Jun 14:100113. doi: 10.1016/j.mcpro.2021.100113. Online ahead of print.ABSTRACTSevere COVID-19 can result in pneumonia and acute respiratory failure. Accumulation of mucus in the airways is a hall mark of the disease and can result in hypoxemia. Here, we show that quantitative proteome analysis of the sputum from severe COVID-19 patients reveal high levels of neutrophil extracellular trap(s) (NETs) components, which was confirmed by microscopy. Extracellular DNA from excessive NET formation can increase sputum viscosity and can lead to acute respiratory distress syndrome (ARDS). Recombinant human ...
Source: Molecular Medicine - June 17, 2021 Category: Molecular Biology Authors: Jane Fisher Tirthankar Mohanty Christofer Karlsson S M Hossein Khademi Erik Malmstr öm Attila Frigyesi Pontus Nordenfelt Johan Malmstrom Adam Linder Source Type: research
Proteome profiling of recombinant DNase therapy in reducing NETs and aiding recovery in COVID-19 patients
Mol Cell Proteomics. 2021 Jun 14:100113. doi: 10.1016/j.mcpro.2021.100113. Online ahead of print.ABSTRACTSevere COVID-19 can result in pneumonia and acute respiratory failure. Accumulation of mucus in the airways is a hall mark of the disease and can result in hypoxemia. Here, we show that quantitative proteome analysis of the sputum from severe COVID-19 patients reveal high levels of neutrophil extracellular trap(s) (NETs) components, which was confirmed by microscopy. Extracellular DNA from excessive NET formation can increase sputum viscosity and can lead to acute respiratory distress syndrome (ARDS). Recombinant human ...
Source: Molecular and Cellular Proteomics : MCP - June 17, 2021 Category: Molecular Biology Authors: Jane Fisher Tirthankar Mohanty Christofer Karlsson S M Hossein Khademi Erik Malmstr öm Attila Frigyesi Pontus Nordenfelt Johan Malmstrom Adam Linder Source Type: research
The Use of Dornase Alfa in the Management of COVID-19-Associated Adult Respiratory Distress Syndrome
CONCLUSIONS: Administration of inhalational dornase alfa via a filtered nebulizer medication system or through an adapter in a ventilator circuit should be considered in all COVID-19-positive patients with ARDS as early in the disease course as possible.PMID:33986957 | PMC:PMC8074548 | DOI:10.1155/2021/8881115 (Source: Critical Care Research and Practice)
Source: Critical Care Research and Practice - May 14, 2021 Category: Intensive Care Authors: Andrew Toma Christina Darwish Michele Taylor Justin Harlacher Ribal Darwish Source Type: research
The use of intrapleural thrombolytic and/or fibrinolytic therapy via indwelling tunneled pleural catheters with or without concurrent anticoagulation usage
We report a relatively low incidence of complications and in particular, bleeding complications in patients receiving intrapleural alteplase for non-draining IPCs. Bleeding episodes occurred in 5/94 (5.3%) patients with no apparent increased risk of bleeding complication, whether receiving anticoagulation or not. Additional study is warranted to identify risk factors for complications, in particular bleeding complications in this patient population.PMID:33745991 | DOI:10.1016/j.chest.2021.03.023 (Source: Chest)
Source: Chest - March 22, 2021 Category: Respiratory Medicine Authors: Christopher R Gilbert Candice L Wilshire Shu-Ching Chang Jed A Gorden Source Type: research
The use of intrapleural thrombolytic and/or fibrinolytic therapy via indwelling tunneled pleural catheters with or without concurrent anticoagulation usage
We report a relatively low incidence of complications and in particular, bleeding complications in patients receiving intrapleural alteplase for non-draining IPCs. Bleeding episodes occurred in 5/94 (5.3%) patients with no apparent increased risk of bleeding complication, whether receiving anticoagulation or not. Additional study is warranted to identify risk factors for complications, in particular bleeding complications in this patient population.PMID:33745991 | DOI:10.1016/j.chest.2021.03.023 (Source: Chest)
Source: Chest - March 22, 2021 Category: Respiratory Medicine Authors: Christopher R Gilbert Candice L Wilshire Shu-Ching Chang Jed A Gorden Source Type: research
Dornase alfa for cystic fibrosis
CONCLUSIONS: There is evidence to show that, compared with placebo, therapy with dornase alfa may improve lung function in people with cystic fibrosis in trials lasting from one month to two years. There was a decrease in pulmonary exacerbations in trials of six months or longer, probably due to treatment. Voice alteration and rash appear to be the only adverse events reported with increased frequency in randomised controlled trials. There is not enough evidence to firmly conclude if dornase alfa is superior to other hyperosmolar agents in improving lung function.PMID:33735508 | DOI:10.1002/14651858.CD001127.pub5 (Source: ...
Source: Cochrane Database of Systematic Reviews - March 18, 2021 Category: General Medicine Authors: Connie Yang Mark Montgomery Source Type: research
Dornase alfa for cystic fibrosis
CONCLUSIONS: There is evidence to show that, compared with placebo, therapy with dornase alfa may improve lung function in people with cystic fibrosis in trials lasting from one month to two years. There was a decrease in pulmonary exacerbations in trials of six months or longer, probably due to treatment. Voice alteration and rash appear to be the only adverse events reported with increased frequency in randomised controlled trials. There is not enough evidence to firmly conclude if dornase alfa is superior to other hyperosmolar agents in improving lung function.PMID:33735508 | DOI:10.1002/14651858.CD001127.pub5 (Source: ...
Source: Cochrane Database of Systematic Reviews - March 18, 2021 Category: General Medicine Authors: Connie Yang Mark Montgomery Source Type: research
Dornase alfa for cystic fibrosis
CONCLUSIONS: There is evidence to show that, compared with placebo, therapy with dornase alfa may improve lung function in people with cystic fibrosis in trials lasting from one month to two years. There was a decrease in pulmonary exacerbations in trials of six months or longer, probably due to treatment. Voice alteration and rash appear to be the only adverse events reported with increased frequency in randomised controlled trials. There is not enough evidence to firmly conclude if dornase alfa is superior to other hyperosmolar agents in improving lung function.PMID:33735508 | DOI:10.1002/14651858.CD001127.pub5 (Source: ...
Source: Cochrane Database of Systematic Reviews - March 18, 2021 Category: General Medicine Authors: Connie Yang Mark Montgomery Source Type: research
Dornase alfa for cystic fibrosis
CONCLUSIONS: There is evidence to show that, compared with placebo, therapy with dornase alfa may improve lung function in people with cystic fibrosis in trials lasting from one month to two years. There was a decrease in pulmonary exacerbations in trials of six months or longer, probably due to treatment. Voice alteration and rash appear to be the only adverse events reported with increased frequency in randomised controlled trials. There is not enough evidence to firmly conclude if dornase alfa is superior to other hyperosmolar agents in improving lung function.PMID:33735508 | DOI:10.1002/14651858.CD001127.pub5 (Source: ...
Source: Cochrane Database of Systematic Reviews - March 18, 2021 Category: General Medicine Authors: Connie Yang Mark Montgomery Source Type: research
Timing of dornase alfa inhalation for cystic fibrosis
CONCLUSIONS: The current evidence derived from a small number of participants does not indicate that inhalation of dornase alfa after airway clearance techniques is more or less effective than the traditional recommendation to inhale nebulised dornase alfa 30 minutes prior to airway clearance techniques, for most outcomes. For children with well-preserved lung function, inhalation before airway clearance may be more beneficial for small airway function than inhalation after. However, this result relied on a measure with high variability and trials with variable follow-up. In the absence of strong evidence to indicate that ...
Source: Cochrane Database of Systematic Reviews - March 9, 2021 Category: General Medicine Authors: Ruth Dentice Mark Elkins Source Type: research
